JC: Reversal of DOACs with Andexanet Alfa. St.Emlyn’s
How convincing were the early results for andexanet alfa in major bleeding associated with factor Xa inhibitors? This 2016 appraisal examines an interim report, distinguishing laboratory reversal from clinical haemostasis and questioning whether limited, unblinded data could establish effectiveness and safety.
JC: Reversal of DOACs with Andexanet Alfa. St.Emlyn’s Read More








